The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a new evaluation tool.

Exelixis delivers a strong Q1 performance with raised 2025 guidance, robust Cabometyx sales, and share buybacks. Read the ...

Merck (NYSE:MRK) is set to showcase significant research advancements, including updates on its KEYTRUDA indications at the upcoming ASCO Annual Meeting, which could enhance its oncology footprint.

IO Biotech was named to Fast Company’s World’s Most Innovative Companies of 2025 list for its potentially game-changing approach to immune-modulatory cancer vaccines, earning its place on the coveted ...

Buried in a technical document released by the Centers for Medicare and Medicaid Services is a convoluted paragraph that may ...